Compare BioNTech SE - ADR (BNTX) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs iShares MSCI South Korea ETF — how do they compare? BioNTech SE - ADR trades at $93.17 (market cap $23.31B), while iShares MSCI South Korea ETF trades at $174.97. The key difference: iShares MSCI South Korea ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | EWY | |
|---|---|---|
Market Cap | $23.31B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $119.34 | $219.20 |
52-Week Low | $83.89 | $71.22 |
Enterprise Value | $6.60B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
EWY, the iShares MSCI South Korea ETF, trades at $174.49, up 6.97% in 24 hours, with a neutral technical signal overall. Recent news highlights South Korea's semiconductor sector volatility and government support initiatives, including a $3.52 billion fund for chip materials. The ETF's performance is tied to heavyweights like Samsung and SK Hynix, which have faced sharp declines amid AI-driven market swings.
Outlook remains cautious due to sector concentration risks and foreign capital outflows, but long-term potential exists if semiconductor demand stabilizes. Investors face volatility from leveraged ETF speculation curbs and global tech sentiment shifts, requiring careful risk assessment amid mixed analyst views.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
